Turnover: 3.03 billion EUR (2022)

Country: France

Created in 1929 under the name of Laboratoires Beaufour, IPSEN's (Institut des produits de synthèse et d'extraction naturelle) activities have historically profited from plant-based medicines.this is illustrated by the success of Romarène, a medicine for digestive disorders based on Rosemary extracts, right from the company's inception.

IPSEN's drug production is grouped under the "family health" segment, which accounts for 16% of the Group's business. In addition to its cutting-edge therapeutic activities, illustrated by research partnerships with the CNRS and MIT, IPSEN specializes in France in the gastroenterology and cognitive disorders markets. In particular, it is the creator of SMECTA and, since 1994, the sole distributor of Dysport.

IPSEN has historically focused on Anglo-Saxon markets. Its flagship herbal product is SMEBIOCTA, a herbal solution for regulating intestinal flora.

News

Botox: botulinum toxin boosts pharma's bottom line 02/08/2023

  • The United States accounts for half of the global botulinum toxin market.
  • Last year, Botox accounted for $5.2 billion in worldwide sales for AbbVie, with equal shares between aesthetics (+21% excluding currency effect) and therapeutics (+13%).
  • In the United States, Dysport (Ipsen) has only 5% of the therapeutic market, compared with 30% in France.
  • In aesthetics in the US, Ipsen has an estimated share of between 20% and 25%.
  • Of the French laboratory Ipsen's half-year sales of 1.5 billion euros (+7%), 319 million (+32%) come from botulinum toxin sold in therapeutics and, in some countries, in aesthetics.
  • Botox holds 40% to 50% of the therapeutic market in France, compared with 30% for Ipsen.

Ipsen exceeds its targets, helped by its Botox competitor 11/02/2023

  • Family-owned laboratory controlled by descendants of Henri Beaufour
  • Ipsen exceeds its targets
  • Strong growth in sales of Dysport, its botulinum toxin competitor to Botox, generating €594 million in sales

Ipsen bets $1 billion on a biotech to treat liver disease 21/01/2023

  • Ipsen announces largest acquisition since the sale of Smecta (its family healthcare division) in 2022
  • french pharmaceutical group to launch $952 million takeover bid for US biotech Albireo
  • By 2021, Ipsen has added 16 new molecules to its portfolio

Ipsen strengthens its position in the dynamic rare diseases segment 09/01/2023

  • Ipsen to pay €1 billion for US biotech Albireo
  • The market for rare diseases is close to $150 billion

Financial Data

DUNS: 308197185

Legal Name: IPSEN PHARMA

Address: 65 QUAI GEORGES GORSE , 92100 BOULOGNE-BILLANCOURT

Number of employees: Entre 500 et 999 salariés (2020)

Capital: 7 755 053 EUR


Financial Data:

Year 2021 2020 2019 2018 2017 2016 2015
Turnover 1 635 000 000 1 567 000 000 1 536 600 000 1 340 000 000 1 206 000 000 1 084 567 984 1 038 847 015
Gross margin (€) 1 303 900 000 1 270 800 000 1 158 400 000 1 087 500 000 945 100 000 808 112 464 -
EBITDA (€) 400 700 000 464 400 000 320 900 000 212 200 000 172 500 000 183 046 982 -
Operating profit (€) 306 500 000 338 200 000 244 500 000 144 000 000 112 400 000 155 291 033 -
Net profit (€) 96 000 000 222 000 000 345 200 000 127 000 000 233 000 000 178 518 785 185 808 126
Turnover growth rate (%) 4,3 2,1 14,7 11 11,3 4,4 -
Ebitda margin rate (%) 24,5 29,6 20,9 15,8 14,3 16,9 -
Operating margin rate (%) 18,7 21,6 15,9 10,7 9,3 14,3 -
Working Capital (turnover days) -217,5 -229,3 -88,2 -62 -67 -144,5 -
Working Capital requirements (turnover days) 29,4 44,9 35,8 18,1 16 35,8 -
Net margin (%) 5,9 14,2 22,5 9,5 19,3 16,5 -
Added value / Turnover (%) 31,1 35,6 28,4 17,6 18,4 21,4 -
Wages and social charges (€) 122 900 000 111 300 000 107 600 000 141 600 000 136 300 000 127 177 208 -
Salaries / Turnover (%) 7,5 7,1 7 10,6 11,3 11,7 -

Company Managers:

Position First Name Last Name Age Linkedin
Président David LOEW 56
Directeur général François-Maurice GARNIER 61
Directeur général Aidan MURPHY 57
Directeur général Stéphane ANDRE 65
Directeur général Stéphane SIMON 54
Directeur général Régis MULOT 57
Directeur général Henri GUENARD 44
Directeur général Aymeric LE CHATELIER 54
Directeur général Patrice ZAGAME 63
Directeur général Bartosz, Daniel BEDNARZ 53
Directeur général Philippe DE SORBIER DE POUGNADORESSE 51
Directeur général Howard MAYER 61

Studies mentioning this company

> Besoin de plus d'information sur cette entreprise (SWOT, PESTEL, son marché) ? Demandez à SectorGPT (gratuit)

 

Ask Sector-GPT  

Sector-GPT est la première IA dédiée aux informations sectorielles.